Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients-A Single-Institution Retrospective Review.

Authors

• Julia M. Hurley, Michigan State University College of Human Medicine Medical Student
• Ryleigh Krueger, Corewell Health West
• Kellie Joyce, Corewell Health West
• James Stanley, Corewell Health West
• Mary Waskerwitz-Freyer, Corewell Health West
• Marielle Klunder, Corewell Health West
• David J. Hoogstra, Corewell Health West

Document Type

Article

Publication Date

7-2026

Publication Title

Pediatric Blood & Cancer

Abstract

Blinatumomab, a CD19xCD3 bispecific T-cell engager, has become standard therapy for children with de novo B-cell acute lymphoblastic leukemia (B-ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients. At our institution, 31 children with B-ALL received continuous intravenous (IV) blinatumomab from January 1, 2018, to December 31, 2024. Logistical issues requiring clinical intervention occurred in 16 (51.6%) patients, with 57.8% of these issues resulting in hospitalization. After receiving blinatumomab, 26 patients (83.9%) required intravenous immunoglobulin (IVIG). These results support investigations into alternative methods of blinatumomab delivery and the impact of blinatumomab on immune function in pediatric patients with B-ALL.

First Page

e70599

Last Page

e70599

Recommended Citation

Hurley JM, Krueger R, Joyce K, Stanley J, Waskerwitz‐Freyer M, Klunder M, et al.[Hoogstra DJ]. Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review. Pediatr Blood Cancer. 2026:e70599. doi: 10.1002/1545-5017.70599. PMID: 42533615.

Comments

Helen DeVos Children's Hospital

DOI

10.1002/1545-5017.70599

ISSN

1545-5017

PubMed ID

42533615